Pub Date : 2026-02-01Epub Date: 2025-12-11DOI: 10.1016/j.lanmic.2025.101262
Giorgia Gon PhD , Sokvy Ma MSc , Alexander M Aiken PhD , Prof Stephanie J Dancer PhD , Prof Wendy J Graham PhD , Stephen Nash MSc , Vandarith Nov MSc , Sovathiro Mao MSc , Bernice Sarpong MSc , Maxine Pepper MSc , Sreytouch Vong MSc , Vouchnea Tang BA , Jennifer Thompson PhD , Ir Por PhD
Background
Cleanliness of near-patient hospital surfaces is essential for preventing health care-associated infections and the spread of antimicrobial-resistant pathogens. Randomised evaluations of cleaning interventions have not been done in low-resource settings. We assessed the effectiveness of a hospital-based training intervention (Clean Frontline) to improve the microbiological cleanliness of near-patient surfaces.
Methods
In this stepped-wedge, cluster-randomised trial in 13 Cambodian referral hospitals, we defined four steps (timings) that define the transition from control to intervention. All eligible public referral hospitals (district or provincial) in three selected provinces consented to participate. Pre-intervention, environmental cleaning practices remained unchanged. The multicomponent intervention selected, trained, and supervised facility cleaning champions, who in turn trained and supervised hospital cleaners. The primary outcome was microbiological cleanliness of near-patient surfaces, assessed using dipslides (a surface with <2·5 colony-forming units per cm2 was classified as clean). 30 samples per hospital were collected monthly over 10 months. Outcome data collection and analysis teams were masked to treatment allocation. The primary outcome was estimated at surface level (primary analysis, odds ratio) and hospital level (risk difference), using an intention-to-treat approach and adjusted for a-priori confounders: temperature, patient numbers, beds per cleaner, and surface type. This trial is registered with ClinicalTrials.gov, NCT05540886, and is complete.
Findings
Across the 13 participating hospitals, a total of 53 champions and 51 cleaners were trained. Outcomes were measured monthly between May 3, 2022, and March 23, 2023. We collected 3900 samples, 3822 of which were used in the analyses. We observed a positive, although non-significant, effect of the intervention on cleanliness in the surface analysis (odds ratio 1·39 [95% CI 0·95–2·03], p=0·081). The hospital-level analysis indicated a significant improvement of 5·04 percentage points (95% CI 0·76–9·33, p=0·026).
Interpretation
Improving microbiological cleanliness of near-patient surfaces in hospitals in low-resource settings through the delivery of context-appropriate training and support is feasible. Further research should test this intervention with a wider number of clusters. Lessons learnt from the implementation will inform WHO roll-out of the training package.
Funding
Who Gives A Crap and the Reckitt Global Hygiene Institute.
背景:医院近病人表面的清洁对于预防卫生保健相关感染和耐药病原体的传播至关重要。在资源匮乏的环境中,尚未对清洁干预措施进行随机评估。我们评估了以医院为基础的培训干预(清洁前线)的有效性,以提高患者附近表面的微生物清洁度。方法:在13家柬埔寨转诊医院进行的这一楔形分步、聚类随机试验中,我们定义了四个步骤(时间)来定义从控制到干预的过渡。在选定的三个省,所有符合条件的公立转诊医院(区或省)都同意参与。干预前的环境清洁做法保持不变。多组分干预选择,培训和监督设施清洁冠军,他们反过来培训和监督医院清洁工。主要结果是用蘸片评估患者附近表面的微生物清洁度(2级表面为清洁)。每家医院在10个月内每月采集30份样本。结果数据收集和分析小组对治疗分配不知情。主要结局在表面水平(主要分析,优势比)和医院水平(风险差异)进行估计,使用意向治疗方法,并根据先验混杂因素进行调整:温度、患者数量、每个清洁工的床位和表面类型。该试验已在ClinicalTrials.gov注册,编号NCT05540886,并且已经完成。结果:在13家参与医院中,共有53名冠军和51名清洁工接受了培训。结果在2022年5月3日至2023年3月23日期间每月测量一次。我们收集了3900个样本,其中3822个用于分析。在表面分析中,我们观察到干预对清洁度的积极影响,尽管不显著(优势比1.39 [95% CI 0.95 - 2.03], p= 0.081)。医院水平分析显示,显著改善5.04个百分点(95% CI 0.76 - 9.33, p= 0.026)。解释:在资源匮乏的环境中,通过提供适合环境的培训和支持,改善医院近病人表面的微生物清洁度是可行的。进一步的研究应该在更广泛的群体中检验这种干预措施。从实施中吸取的经验教训将为世卫组织推出一揽子培训提供参考。资助:Who Gives A Crap和利洁时全球卫生研究所。
{"title":"Impact of a multicomponent training intervention (Clean FrontLine) on microbiological cleanliness in Cambodian referral hospitals: a multicentre, stepped-wedge, cluster-randomised trial","authors":"Giorgia Gon PhD , Sokvy Ma MSc , Alexander M Aiken PhD , Prof Stephanie J Dancer PhD , Prof Wendy J Graham PhD , Stephen Nash MSc , Vandarith Nov MSc , Sovathiro Mao MSc , Bernice Sarpong MSc , Maxine Pepper MSc , Sreytouch Vong MSc , Vouchnea Tang BA , Jennifer Thompson PhD , Ir Por PhD","doi":"10.1016/j.lanmic.2025.101262","DOIUrl":"10.1016/j.lanmic.2025.101262","url":null,"abstract":"<div><h3>Background</h3><div>Cleanliness of near-patient hospital surfaces is essential for preventing health care-associated infections and the spread of antimicrobial-resistant pathogens. Randomised evaluations of cleaning interventions have not been done in low-resource settings. We assessed the effectiveness of a hospital-based training intervention (Clean Frontline) to improve the microbiological cleanliness of near-patient surfaces.</div></div><div><h3>Methods</h3><div>In this stepped-wedge, cluster-randomised trial in 13 Cambodian referral hospitals, we defined four steps (timings) that define the transition from control to intervention. All eligible public referral hospitals (district or provincial) in three selected provinces consented to participate. Pre-intervention, environmental cleaning practices remained unchanged. The multicomponent intervention selected, trained, and supervised facility cleaning champions, who in turn trained and supervised hospital cleaners. The primary outcome was microbiological cleanliness of near-patient surfaces, assessed using dipslides (a surface with <2·5 colony-forming units per cm<sup>2</sup> was classified as clean). 30 samples per hospital were collected monthly over 10 months. Outcome data collection and analysis teams were masked to treatment allocation. The primary outcome was estimated at surface level (primary analysis, odds ratio) and hospital level (risk difference), using an intention-to-treat approach and adjusted for a-priori confounders: temperature, patient numbers, beds per cleaner, and surface type. This trial is registered with <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>, <span><span>NCT05540886</span><svg><path></path></svg></span>, and is complete.</div></div><div><h3>Findings</h3><div>Across the 13 participating hospitals, a total of 53 champions and 51 cleaners were trained. Outcomes were measured monthly between May 3, 2022, and March 23, 2023. We collected 3900 samples, 3822 of which were used in the analyses. We observed a positive, although non-significant, effect of the intervention on cleanliness in the surface analysis (odds ratio 1·39 [95% CI 0·95–2·03], p=0·081). The hospital-level analysis indicated a significant improvement of 5·04 percentage points (95% CI 0·76–9·33, p=0·026).</div></div><div><h3>Interpretation</h3><div>Improving microbiological cleanliness of near-patient surfaces in hospitals in low-resource settings through the delivery of context-appropriate training and support is feasible. Further research should test this intervention with a wider number of clusters. Lessons learnt from the implementation will inform WHO roll-out of the training package.</div></div><div><h3>Funding</h3><div>Who Gives A Crap and the Reckitt Global Hygiene Institute.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 2","pages":"Article 101262"},"PeriodicalIF":20.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-12-22DOI: 10.1016/j.lanmic.2025.101279
Cara Adolph PhD , Simon C Mendelsohn PhD , Laura E Via PhD , Leonardo Martinez PhD , Cecilia S Lindestam Arlehamn PhD , Prof David M Lewinsohn PhD , Jordi B Torrelles PhD , Prof Philip C Hill MD
Tuberculosis remains a leading cause of death, underscoring the urgent need for a new vaccine. Progress in vaccine development is hampered by incomplete understanding of how Mycobacterium tuberculosis causes infection and disease, and of protective immunity following natural infection and vaccination. Addressing these gaps requires biological samples from tuberculosis cases and contacts or healthy controls as well as from protected and unprotected vaccinated individuals. Numerous observational studies and clinical trials on tuberculosis are conducted each year, collecting and storing diverse samples—including blood derivatives, urine, sputum, saliva, and even radiographic images—from participants. In this Personal View, we suggest that pooling samples from these studies could enable the scientific community to address important and understudied research questions at an unprecedented scale. This approach could generate new insights into fundamental disease mechanisms and the requirements for an effective vaccine. We propose linking existing biorepositories from tuberculosis studies worldwide to facilitate large-scale studies and accelerate breakthroughs in tuberculosis vaccine development.
{"title":"The need for interconnected global biorepositories from tuberculosis studies to address fundamental questions at scale","authors":"Cara Adolph PhD , Simon C Mendelsohn PhD , Laura E Via PhD , Leonardo Martinez PhD , Cecilia S Lindestam Arlehamn PhD , Prof David M Lewinsohn PhD , Jordi B Torrelles PhD , Prof Philip C Hill MD","doi":"10.1016/j.lanmic.2025.101279","DOIUrl":"10.1016/j.lanmic.2025.101279","url":null,"abstract":"<div><div>Tuberculosis remains a leading cause of death, underscoring the urgent need for a new vaccine. Progress in vaccine development is hampered by incomplete understanding of how <em>Mycobacterium tuberculosis</em> causes infection and disease, and of protective immunity following natural infection and vaccination. Addressing these gaps requires biological samples from tuberculosis cases and contacts or healthy controls as well as from protected and unprotected vaccinated individuals. Numerous observational studies and clinical trials on tuberculosis are conducted each year, collecting and storing diverse samples—including blood derivatives, urine, sputum, saliva, and even radiographic images—from participants. In this Personal View, we suggest that pooling samples from these studies could enable the scientific community to address important and understudied research questions at an unprecedented scale. This approach could generate new insights into fundamental disease mechanisms and the requirements for an effective vaccine. We propose linking existing biorepositories from tuberculosis studies worldwide to facilitate large-scale studies and accelerate breakthroughs in tuberculosis vaccine development.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 2","pages":"Article 101279"},"PeriodicalIF":20.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145835024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-01-06DOI: 10.1016/j.lanmic.2025.101277
Victoria T Chu MD MPH , Natasha Spottiswoode MD DPhil , Ryan Ward BS , Deborah S Yokoe MD , Lynn Ramirez-Avila MD , Maira S Phelps BS , Abigail Glascock PhD , Emily D Crawford PhD , Jack Kamm PhD , Samantha Hao MD , Lucy Li PhD , David Dynerman PhD , Eric Waltari PhD , Saba Nafees PhD , Katrina L Kalantar PhD , Saharai Caldera BS , Sharline Madera MD , Estella Sanchez Guerrero PhD , Daniel Ivashin BS , Paula Hayakawa Serpa MD , Charles R Langelier MD PhD
Advances in genomic technologies have revolutionised practices for hospital infection prevention and control programmes. In this Personal View, we describe a genomic epidemiology service called the Rapid Response (RR) programme at University of California, San Francisco, a large academic medical centre. In collaboration with the hospital infection-prevention team, the RR programme uses whole-genome sequencing and metagenomic next-generation sequencing for outbreak investigations, special interest analyses of emerging pathogens, and surveillance of high-priority microbes. Over 7 years (2017–24), the RR programme conducted a diversity of outbreak investigations and other analyses; most investigations ruled out transmission, and the rapid turnaround of genomic results averted further resource-intensive work. Longitudinal surveillance enabled early detection of changing incidence trends and guided timely infection-prevention responses. Our experiences with the RR programme build upon growing evidence that genomic epidemiology programmes enhance hospital infection prevention and control, augment priority pathogen surveillance, and improve patient safety.
{"title":"Implementation and outcomes of a rapid response genomic hospital epidemiology programme at an academic medical centre over 7 years","authors":"Victoria T Chu MD MPH , Natasha Spottiswoode MD DPhil , Ryan Ward BS , Deborah S Yokoe MD , Lynn Ramirez-Avila MD , Maira S Phelps BS , Abigail Glascock PhD , Emily D Crawford PhD , Jack Kamm PhD , Samantha Hao MD , Lucy Li PhD , David Dynerman PhD , Eric Waltari PhD , Saba Nafees PhD , Katrina L Kalantar PhD , Saharai Caldera BS , Sharline Madera MD , Estella Sanchez Guerrero PhD , Daniel Ivashin BS , Paula Hayakawa Serpa MD , Charles R Langelier MD PhD","doi":"10.1016/j.lanmic.2025.101277","DOIUrl":"10.1016/j.lanmic.2025.101277","url":null,"abstract":"<div><div>Advances in genomic technologies have revolutionised practices for hospital infection prevention and control programmes. In this Personal View, we describe a genomic epidemiology service called the Rapid Response (RR) programme at University of California, San Francisco, a large academic medical centre. In collaboration with the hospital infection-prevention team, the RR programme uses whole-genome sequencing and metagenomic next-generation sequencing for outbreak investigations, special interest analyses of emerging pathogens, and surveillance of high-priority microbes. Over 7 years (2017–24), the RR programme conducted a diversity of outbreak investigations and other analyses; most investigations ruled out transmission, and the rapid turnaround of genomic results averted further resource-intensive work. Longitudinal surveillance enabled early detection of changing incidence trends and guided timely infection-prevention responses. Our experiences with the RR programme build upon growing evidence that genomic epidemiology programmes enhance hospital infection prevention and control, augment priority pathogen surveillance, and improve patient safety.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 2","pages":"Article 101277"},"PeriodicalIF":20.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145946565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-01-22DOI: 10.1016/j.lanmic.2025.101273
Johanna Rhodes PhD , Sui Ting Hui MRes , Sarah Dellière MD , Richard C Summerbell PhD , James A Scott PhD , Amtoj Kaur MSc , Richard C Barton PhD , Rodrigo Leitao MSc , Samuel Hemmings MSc , Rebeca Goiriz MD , Jonathan Lambourne PhD , Rhys A Farrer PhD , Silke Schelenz PhD , Prof Roderick J Hay DM , Prof Andrew M Borman PhD , Prof Anuradha Chowdhary MD , Alireza Abdolrasouli PhD , Prof Matthew C Fisher PhD
Background
Trichophyton species cause the greatest burden of dermatophytosis worldwide, with the Trichophyton mentagrophytes species complex being particularly associated with the emergence of new aggressive infections. One emerging species, Trichophyton indotineae is notable for its clinical resistance to terbinafine antifungal treatment and rapid global spread. In this study we aim to characterise the epidemiology of this emerging pathogen using genomics.
Methods
In this retrospective genomic epidemiology study, to better understand the epidemiology of this disease, we sourced isolates collected from patients with severe cases of dermatophytosis (identified either by internal transcribed spacer sequencing or phenotypic characterisation) in the UK, Ireland, France, Canada, and India for the period 2014–23, including the T indotineae type strain from Japan. We used whole-genome sequencing to confirm 90 isolates were T indotineae, and antifungal susceptibility testing to assess susceptibility to terbinafine.
Findings
103 cases of severe dermatophytosis caused by Trichophyton species collected between 2018 and 2023 in the UK, France, Canada, Ireland, and India were included in this study. Susceptibility testing indicated that 63 (70%) of 90 T indotineae isolates were resistant to terbinafine (minimum inhibitory concentration [MIC] ≥0·5 mg/L). Pairwise genetic distances showed very high identity with only 147 (range 1–414) single-nucleotide polymorphisms (SNPs) separating isolates that were nested within a monophyletic phylogeny, supporting a single evolutionary origin of T indotineae. Genome-wide analyses identified multiple non-synonymous SNPs in SQLE (ERG1), the squalene epoxidase target of terbinafine, that were associated with terbinafine in vitro resistance of 0·5 mg/L or higher. However, six isolates exhibited high MIC values without SQLE mutations, suggesting the presence of alternative resistance mechanisms.
Interpretation
That no clear geographical clustering of isolates was observed confirms the rapid transcontinental spread of T indotineae from its likely centre of diversity in Asia. Our findings highlight the importance of better genomic surveillance to understand and manage this severe and rapidly emerging terbinafine-resistant dermatophyte.
{"title":"Emerging terbinafine-resistant Trichophyton indotineae between 2018 and 2023: a multinational genomic epidemiology study","authors":"Johanna Rhodes PhD , Sui Ting Hui MRes , Sarah Dellière MD , Richard C Summerbell PhD , James A Scott PhD , Amtoj Kaur MSc , Richard C Barton PhD , Rodrigo Leitao MSc , Samuel Hemmings MSc , Rebeca Goiriz MD , Jonathan Lambourne PhD , Rhys A Farrer PhD , Silke Schelenz PhD , Prof Roderick J Hay DM , Prof Andrew M Borman PhD , Prof Anuradha Chowdhary MD , Alireza Abdolrasouli PhD , Prof Matthew C Fisher PhD","doi":"10.1016/j.lanmic.2025.101273","DOIUrl":"10.1016/j.lanmic.2025.101273","url":null,"abstract":"<div><h3>Background</h3><div><em>Trichophyton</em> species cause the greatest burden of dermatophytosis worldwide, with the <em>Trichophyton mentagrophytes</em> species complex being particularly associated with the emergence of new aggressive infections. One emerging species, <em>Trichophyton indotineae</em> is notable for its clinical resistance to terbinafine antifungal treatment and rapid global spread. In this study we aim to characterise the epidemiology of this emerging pathogen using genomics.</div></div><div><h3>Methods</h3><div>In this retrospective genomic epidemiology study, to better understand the epidemiology of this disease, we sourced isolates collected from patients with severe cases of dermatophytosis (identified either by internal transcribed spacer sequencing or phenotypic characterisation) in the UK, Ireland, France, Canada, and India for the period 2014–23, including the <em>T indotineae</em> type strain from Japan. We used whole-genome sequencing to confirm 90 isolates were <em>T indotineae</em>, and antifungal susceptibility testing to assess susceptibility to terbinafine.</div></div><div><h3>Findings</h3><div>103 cases of severe dermatophytosis caused by <em>Trichophyton</em> species collected between 2018 and 2023 in the UK, France, Canada, Ireland, and India were included in this study. Susceptibility testing indicated that 63 (70%) of 90 <em>T indotineae</em> isolates were resistant to terbinafine (minimum inhibitory concentration [MIC] ≥0·5 mg/L). Pairwise genetic distances showed very high identity with only 147 (range 1–414) single-nucleotide polymorphisms (SNPs) separating isolates that were nested within a monophyletic phylogeny, supporting a single evolutionary origin of <em>T indotineae</em>. Genome-wide analyses identified multiple non-synonymous SNPs in <em>SQLE</em> (<em>ERG1</em>), the squalene epoxidase target of terbinafine, that were associated with terbinafine in vitro resistance of 0·5 mg/L or higher. However, six isolates exhibited high MIC values without <em>SQLE</em> mutations, suggesting the presence of alternative resistance mechanisms.</div></div><div><h3>Interpretation</h3><div>That no clear geographical clustering of isolates was observed confirms the rapid transcontinental spread of <em>T indotineae</em> from its likely centre of diversity in Asia. Our findings highlight the importance of better genomic surveillance to understand and manage this severe and rapidly emerging terbinafine-resistant dermatophyte.</div></div><div><h3>Funding</h3><div>None.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 2","pages":"Article 101273"},"PeriodicalIF":20.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-24DOI: 10.1016/j.lanmic.2025.101295
Md Zakiul Hassan, Susan Khader Ibrahim, Eli Harriss, Peter Horby, Piero Olliaro, Amanda Rojek
Nipah virus is a priority pathogen with high mortality and pandemic potential. Therapies for Nipah virus disease, such as monoclonal antibodies and antivirals, are under development and require clinical trials for evaluation. However, designing such trials is challenging due to the limited understanding of the clinical characteristics, pathogenesis, and current management of Nipah virus disease. In this Review, we gathered essential data from 59 studies reporting 717 Nipah virus disease cases, to inform trial design. Nearly all patients (618 [99%] of 624) had fever. Neurological symptoms included headache (419 [70%] of 601 patients), confusion (74 [65%] of 114), and altered consciousness (358 [62%] of 580); respiratory symptoms included cough (244 [45%] of 541) and difficulty in breathing (184 [58%] of 317). Imaging data revealed chest abnormalities (29 [80%] of 36) and brain involvement (40 [71%] of 56). Viral RNA was detectable early in illness across various sample types. The median case-fatality rate was 69% (IQR 31-88%), with 51 (26%) of 197 survivors presenting with persistent neurological deficits. Clinical management varied widely, with incomplete reporting limiting insights. Prospective observational studies are needed to generate actionable data on clinical case definitions, predictors of adverse outcomes, current standards of care, and standardised endpoints, to inform future trials.
{"title":"Interpreting the natural history and pathogenesis of Nipah virus disease through clinical data, to inform clinical trial design: a systematic review.","authors":"Md Zakiul Hassan, Susan Khader Ibrahim, Eli Harriss, Peter Horby, Piero Olliaro, Amanda Rojek","doi":"10.1016/j.lanmic.2025.101295","DOIUrl":"https://doi.org/10.1016/j.lanmic.2025.101295","url":null,"abstract":"<p><p>Nipah virus is a priority pathogen with high mortality and pandemic potential. Therapies for Nipah virus disease, such as monoclonal antibodies and antivirals, are under development and require clinical trials for evaluation. However, designing such trials is challenging due to the limited understanding of the clinical characteristics, pathogenesis, and current management of Nipah virus disease. In this Review, we gathered essential data from 59 studies reporting 717 Nipah virus disease cases, to inform trial design. Nearly all patients (618 [99%] of 624) had fever. Neurological symptoms included headache (419 [70%] of 601 patients), confusion (74 [65%] of 114), and altered consciousness (358 [62%] of 580); respiratory symptoms included cough (244 [45%] of 541) and difficulty in breathing (184 [58%] of 317). Imaging data revealed chest abnormalities (29 [80%] of 36) and brain involvement (40 [71%] of 56). Viral RNA was detectable early in illness across various sample types. The median case-fatality rate was 69% (IQR 31-88%), with 51 (26%) of 197 survivors presenting with persistent neurological deficits. Clinical management varied widely, with incomplete reporting limiting insights. Prospective observational studies are needed to generate actionable data on clinical case definitions, predictors of adverse outcomes, current standards of care, and standardised endpoints, to inform future trials.</p>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":" ","pages":"101295"},"PeriodicalIF":20.4,"publicationDate":"2026-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146067646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-19DOI: 10.1016/j.lanmic.2025.101297
Thibaut Vanbaelen, Irith De Baetselier, Achilleas Tsoumanis, Bernadette Hensen, Dorien Van den Bossche, Chris Kenyon
{"title":"Reversing resistance? Declines in macrolide-resistant STIs following antimicrobial stewardship interventions in Belgium.","authors":"Thibaut Vanbaelen, Irith De Baetselier, Achilleas Tsoumanis, Bernadette Hensen, Dorien Van den Bossche, Chris Kenyon","doi":"10.1016/j.lanmic.2025.101297","DOIUrl":"https://doi.org/10.1016/j.lanmic.2025.101297","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":" ","pages":"101297"},"PeriodicalIF":20.4,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146031178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}